Clinical Trial Update: Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CB-839 in combination with paclitaxel in participants with advanced triple negative breast cancer completed with results posted in 2022…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CB-839 (telaglenastat)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Calithera Biosciences, Inc | Conditions: Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-09-28